Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Crinetics Pharmaceuticals Inc
(NQ:
CRNX
)
56.69
+0.73 (+1.30%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Crinetics Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
What Analysts Are Saying About Crinetics Pharmaceuticals Stock
September 27, 2024
Via
Benzinga
A Closer Look at 11 Analyst Recommendations For Crinetics Pharmaceuticals
August 09, 2024
Via
Benzinga
CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
August 08, 2024
CRNX stock results show that Crinetics Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
July 14, 2024
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
July 01, 2024
Via
Benzinga
Forecasting The Future: 11 Analyst Projections For Crinetics Pharmaceuticals
June 28, 2024
Via
Benzinga
17 Analysts Have This To Say About Crinetics Pharmaceuticals
June 04, 2024
Via
Benzinga
18 Analysts Have This To Say About Crinetics Pharmaceuticals
May 14, 2024
Via
Benzinga
7 Biotech Stocks to Boost Your Portfolio to Peak Health
June 26, 2024
With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.
Via
InvestorPlace
Nvidia To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
June 04, 2024
Via
Benzinga
Analog Devices Posts Strong Earnings, Joins TJX, Williams-Sonoma And Other Big Stocks Moving Higher On Wednesday
May 22, 2024
Via
Benzinga
CRNX Stock Earnings: Crinetics Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
May 09, 2024
CRNX stock results show that Crinetics Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
The Analyst Verdict: Crinetics Pharmaceuticals In The Eyes Of 6 Experts
February 29, 2024
Via
Benzinga
Crinetics Pharmaceuticals: Q4 Earnings Insights
February 28, 2024
Via
Benzinga
Crinetics Pharmaceuticals Earnings Preview
February 27, 2024
Via
Benzinga
Endocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's Why
March 19, 2024
Crinetics Pharmaceuticals unveils PATHFNDR-2 Phase 3 results for paltusotine in acromegaly treatment. Statistically significant efficacy & safety, with plans for FDA submission in 2024.
Via
Benzinga
Exposures
Product Safety
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
March 19, 2024
Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter EPS results.
Via
Benzinga
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
March 19, 2024
U.S. stocks were mixed, with the Dow Jones index gaining around 75 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Analyst Scoreboard: 4 Ratings For Crinetics Pharmaceuticals
December 19, 2023
Via
Benzinga
8 Analysts Have This to Say About Crinetics Pharmaceuticals
November 20, 2023
Via
Benzinga
Biotech Stock Crinetics Jets Higher On Second Phase 3 Trial Win
March 19, 2024
Biotech stock Crinetics Pharmaceuticals rocketed early Tuesday after solid trial results for its oral growth hormone treatment.
Via
Investor's Business Daily
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday
March 01, 2024
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
January 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 28, 2023
Via
Benzinga
11 Analysts Have This to Say About Crinetics Pharmaceuticals
October 24, 2023
Via
Benzinga
Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study
December 19, 2023
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
October 09, 2023
Via
Benzinga
7 Speculative Stocks Set to Explode Higher
October 03, 2023
On the search for high-risk, high-reward opportunities? Consider taking a look at these seven speculative stocks.
Via
InvestorPlace
Top 4 Health Care Stocks That Should Keep You Up At Night
September 21, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Up 83% in 5 Days, Is Crinetics Pharmaceuticals a Buy?
September 19, 2023
Despite good results in phase 3 trials, there are barriers to its drug candidate's success.
Via
The Motley Fool
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.